Cited 0 times in
Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 양규현 | - |
dc.date.accessioned | 2017-11-02T08:16:12Z | - |
dc.date.available | 2017-11-02T08:16:12Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2287-6375 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154276 | - |
dc.description.abstract | BACKGROUND: The purpose of this prospective, open-label, observational study was to assess the fracture preventing effect of Maxmarvil® tablets (alendronate 5 mg + calcitriol 0.5 µg) in patients with osteoporosis and to evaluate the change in bone mineral density (BMD) at the minimum 1-year follow-up. METHODS: In this multicenter observational study, 691 patients with osteoporosis (aged 50 years or older) were treated with alendronate 5 mg + calcitriol 0.5 µg/day during their normal course of care. Patients were assessed at baseline and at 6 and 12 months. Baseline characteristics (including age, gender, concomitant disease, and baseline fractures) were evaluated. RESULTS: From among the 848 participants, 149 individuals were lost to follow-up at the time of the study and 8 people had died. The 691 participants (54 men and 637 women) finished the follow-up study and completed the questionnaire. The mean age of the participants was 71.5 years (range, 50-92 years; mean age, 72.3 years for men and 71.4 years for women). Osteoporotic fracture occurred in 19 patients (2.7%). BMD of the lumbar spine and hip was improved by 5% and 1.5% at the latest follow-up. At the latest follow-up, 24 patients (3.5%) complained of drug-related complications such as dyspepsia, constipation, and nausea. CONCLUSIONS: This prospective observational study demonstrated that alendronate 5 mg + calcitriol 0.5 µg/day had a preventive effect on osteoporotic fracture and it increased the BMD of the lumbar spine by 5% at the latest follow-up. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Society for Bone and Mineral Research | - |
dc.relation.isPartOf | Journal of Bone Metabolism | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis | - |
dc.type | Article | - |
dc.publisher.location | Korea (South) | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Orthopedic Surgery | - |
dc.contributor.googleauthor | Jun-Il Yoo | - |
dc.contributor.googleauthor | Yong-Chan Ha | - |
dc.contributor.googleauthor | Ye-Yeon Won | - |
dc.contributor.googleauthor | Kyu-Hyun Yang | - |
dc.contributor.googleauthor | Sang-Bum Kim | - |
dc.contributor.googleauthor | Ju-Hyung Yoo | - |
dc.contributor.googleauthor | Dong-Soo Kim | - |
dc.identifier.doi | 10.11005/jbm.2017.24.2.91 | - |
dc.contributor.localId | A02282 | - |
dc.relation.journalcode | J02875 | - |
dc.relation.journalsince | 2012~ | - |
dc.identifier.pmid | 28642852 | - |
dc.relation.journalbefore | ~2011 JBM : Journal of Bone Metabolism | - |
dc.subject.keyword | Alendronate | - |
dc.subject.keyword | Bone density | - |
dc.subject.keyword | Calcitriol | - |
dc.subject.keyword | Osteoporosis | - |
dc.subject.keyword | Osteoporotic fractures | - |
dc.contributor.alternativeName | Yang, Kyu Hyun | - |
dc.contributor.affiliatedAuthor | Yang, Kyu Hyun | - |
dc.citation.title | Journal of Bone Metabolism | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 91 | - |
dc.citation.endPage | 96 | - |
dc.identifier.bibliographicCitation | Journal of Bone Metabolism, Vol.24(2) : 91-96, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 42244 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.